Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 4 records in total 4
    records per page

    Association Between Cystatin C HGNC, Cystatin C HGNC Rangeability and Mortality of COVID-19 MESHD Patients With or Without Type 2 Diabetes Mellitus: An Opportunistic Retrospective Analysis

    Authors: Lei Yang; Dou Xu; Yiqing Tan; Bolin Li; Dan Zhu; Jingbo Wang; Hui Sun; Xinglong Liu; Xiao-Pu Zheng; Ling Zhu; Zhongyu Li

    doi:10.21203/ Date: 2020-11-19 Source: ResearchSquare

    Background: Since December of 2019, novel coronavirus (SARS-CoV-2)-induced pneumonia MESHD ( COVID-19 MESHD) exploded in Wuhan, and rapidly spread throughout China. Patients with COVID-19 MESHD demonstrated quite different appearances and outcomes in clinical manifestations. We aimed to figure out whether risk factors of the cystatin C HGNC (CysC) and the CysC rangeability are influencing the prognosis of COVID-19 MESHD patients with or without type 2 diabetes mellitus MESHD ( T2DM MESHD).Methods: 675 T2DM MESHD patients and 602 non- T2DM MESHD patients were divided into low CysC group, high CysC group and low CysC rangeability group, high CysC rangeability group according to the serum CysC level and the change range of CysC. Demographic characteristics, clinical data and laboratory results of the four groups were collected and analyzed.Results: Our data showed that COVID-19 MESHD patients with high CysC level and CysC rangeability had more organic damage MESHD and higher mortality rate compared to those with low level or low rangeability of CysC. Furthermore, patients with higher CysC level and CysC rangeability also demonstrated higher blood lymphocytes (lymph), C-reactive protein HGNC (CRP), alanine aminotransferase HGNC (ALT), aspartate aminotransferase ( AST HGNC) which may greatly influence disease progression and poor prognosis of COVID-19 MESHD. After adjusting for possible confounders, multivariate analysis revealed that CysC≤0.93mg/dl as a reference, CysC>0.93mg/dl were significantly associated with the risk of heart failure MESHD (OR=2.401, 95% CI: 1.118–5.156) and all-cause death MESHD (OR=2.734, 95% CI: 1.098-6.811); referring to CysC rangeability≤0, CysC rangeability>0 significantly associated with all-cause death MESHD (OR=4.029, 95% CI: 1.864-8.706). Further grouped by T2DM MESHD, these associations were stronger in T2DM MESHD than in non- T2DM MESHD.Conclusions: It suggests that CysC level and CysC rangeability contribute to clinical manifestations and may influence the prognosis of COVID-19 MESHD. The CysC is considered as a potential risk factor of the prognosis of COVID-19 MESHD. Special medical care and appropriate intervention should be performed in COVID-19 MESHD patients with elevated CysC during hospitalization and later clinical follow-up, especially for those with T2DM MESHD.

    Temporal Dynamics in Clinical and Laboratory Manifestations During COVID-19 MESHD Progression

    Authors: Lin-Lin Ye; Wen-Bei Peng; Xiao-Shan Wei; Xu Wang; Zi-Hao Wang; Xuan Xiang; Xiao-Rong Wang; Wei-Bing Yang; Xin-Liang He; Fei Xiang; Yuan Su; Qiong Zhou

    doi:10.21203/ Date: 2020-07-13 Source: ResearchSquare

    BAckground Severe COVID-19 MESHD patients account for most of the mortality of this disease. Early detection of severe cases of the disease remains a major challenge. Here, we performed clinical and laboratory profiling of COVID-19 MESHD to explore the early warning indicators of severe cases.Methods An analysis of the evolution during the hospitalization of clinical and laboratory findings from 78 confirmed COVID-19 MESHD patients and the associated risk factors.Results Of the 78 patients who were classified as un-severe at admission, 60 patients(stable group) were stable as mild cases until discharge, and the remaining 18 patients progressed to severe cases(exacerbated group) during hospitalization. Compared with stable patients, exacerbated patients exhibited older, higher BMI values and higher proportion of smokers. In the exacerbated patients, the median time from onset to deterioration was 7.5 days. Before the time point(days 0–7 from onset), we observed higher-levels of White blood cells(WBC), neutrophil, Neutrophi-Lymphocyte-Ratio(NLR), Lactose-dehydrogenase(LDH), D-dimer, and lower-levels of albumin in the exacerbated group, compared with the stable group. In the second week after the time point, the exacerbated patients displayed lower numbers of lymphocytes, CD3+, and CD8+T-cells, and higher-levels of C-reactive protein HGNC( CRP HGNC), erythrocyte-sedimentation-rate(ESR), Alanine-aminotransferase HGNC(ALT),Aspartate-aminotransferase( AST HGNC), and Interleukin-6 HGNC. In the third week, the highest temperature and the proportion of febrile patients declined. All of the laboratory indicators gradually improved.Conclusions Advanced age and smoking history could be risk factors for COVID-19 MESHD progression. In the early stage, high-levels of WBC and neutrophils, with noticeably increased LDH and D-dimer, could be early indicators of the disease’s conversion from mild to severe, followed by elevated inflammatory markers, liver enzymes, and decreased T-lymphocytes in the next week.

    Liver Function in Novel Coronavirus Disease ( COVID-19 MESHD): A Systematic Review and Meta-Analysis

    Authors: Mohammad Zahedi; Mohammad Yousefi; Mahdi Abounoori; Mohammad Malekan; Fatemeh Tajik; Keyvan Heydari; Parham Mortazavi; Monireh Ghazaeian; Fateme Sheydaee; Amirreza Nasirzadeh; Reza Alizadeh-Navaei

    doi:10.1101/2020.05.20.20108357 Date: 2020-05-23 Source: medRxiv

    Introduction:The outbreak of new coronavirus has become a global public health challenge. Given a consequential liver function, and the high risk of death MESHD coming from liver disorders MESHD, the assessment of Novel Coronavirus Disease MESHD on liver function is importance. Hence, we carried out this meta-analysis to heightening insight into the occult features of COVID 19, which is likely to affect liver function. Method:This study was performed using databases of Web of Science, Scopus, and PubMed. We considered English cross-sectional and case-series papers, which reported available findings on the association between liver injury MESHD and COVID-19 MESHD infection. We used the STATA v.11 and random effect model for data analysis. Result:In this present meta-analysis, 52 papers, including 8,463 COVID-19 MESHD patients, were studied. The prevalence of increased liver enzymes among the patients, including Alanine aminotransferase HGNC, Aspartate aminotransferase, were 30% and 21% in non-severe patients, respectively, which were 38% and 48% in severe patients. The prevalence of increasing C-reactive protein HGNC, Lactate dehydrogenase, D-dimer, and Bilirubin were 55%, 39%, 28%, and 10% in non-severe patients respectively, which were 78%, 75%, 79% and 17% in sever patients.The prevalence of liver toxicity MESHD as a complication of COVID-19 MESHD was 20%.Also patients who have severe condition are 5.54, 4.22, 4.96, 4.13 and 4.34 times more likely to have elevated CRP, ALT, AST HGNC, LDH, D-dimer enzymes retrospectively. Conclusion:Elevation of some liver markers were higher in patients with severe COVID-19 MESHD infection. All to gather, we assumed that abnormal liver markers could act as a prognostic factor for a better survey of COVID-19 MESHD.

    Laboratory features in severe vs. non-severe COVID-19 MESHD patients, a systematic review and meta-analysis

    Authors: Sulmaz Ghahramani; Reza Tabrizi; Kamran B Lankarani; Seyyed mohammad amin Kashani; Shahla Rezaei; Nazanin Zeidi; Maryam Akbari; Seyed Taghi Heydari; Hamed Akbari; Peyman Nowrouzi-sohrabi; Fariba Ahmadizar

    doi:10.21203/ Date: 2020-05-15 Source: ResearchSquare

    OBJECTIVE: Understanding the common laboratory features of COVID-19 MESHD in severe cases versus non-severe patients could be quite useful for clinicians and might help to predict the model of disease progression. MATERIALS AND METHODS: Electronic databases were systematically searched in PubMed, EMBASE, Scopus, Web of ‎Science, and Google Scholar from inception to 3rd of March 2020. Heterogeneity across included ‎studies was determined using Cochrane’s Q test and the I2 statistic. We used the fixed or random-effect models to pool ‎the weighted mean differences (WMDs) or standardized mean differences and 95% confidence ‎intervals (CIs).‎RESULTS:‎ Out of a total of 3009 citations, 17 articles (22 studies, 21 from China and one study from Singapour) with 3396 ranging from 12-1099 patients, ‎were included. Our meta-analyses showed a significant decrease in ‎lymphocyte, monocyte, and eosinophil, hemoglobin, platelet, albumin, serum sodium, lymphocyte to C-reactive protein HGNC ratio (LCR), leukocyte to C-reactive protein HGNC ratio (LeCR), leukocyte to IL-6 HGNC ratio (LeIR), and an increase in the ‎neutrophil, alanine ‎aminotransferase HGNC (ALT), aspartate aminotransferase ( AST HGNC), total bilirubin, blood urea nitrogen (BUN), creatinine (Cr), erythrocyte sedimentation rate (ESR), C-reactive protein HGNC ( CRP HGNC), procalcitonin (PCT), lactate dehydrogenase (LDH), fibrinogen HGNC, prothrombin time (PT), D-dimer, glucose ‎level, and neutrophil to lymphocyte ratio (NLR) in the severe group compared with the non-severe group. However, no significant changes were observed in white blood cells (WBC), ‎ creatine kinase (CK), troponin I, myoglobin HGNC, interleukin-6 HGNC ( IL-6 HGNC), and potassium (K) between the two groups.‎CONCLUSIONS: This meta-analysis provides evidence for the differentiation of severe cases of COVID-19 MESHD based on laboratory test results at the time of hospital admission. Future well-methodologically designed studies from other populations are strongly recommended.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.